organization · Reporting owner
NOVARTIS PHARMA AG
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cellular Biomedicine Group, Inc.CBMG · Entity 142413 | 10% owner | August 11, 2020 | August 14, 2020 |
| PRECISION BIOSCIENCES INCDTIL · Entity 6284 | 10% owner | June 15, 2022 | June 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cellular Biomedicine Group, Inc.
Report date August 11, 2020 · Filed August 14, 2020
Jointly reported with NOVARTIS AG
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,458,257 |
Reported balance
Holding disclosure · report date 2020-08-11 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,458,257 F1: Novartis Pharma AG is the record holder of the securities reported herein. As the parent of Novartis Pharma AG, Novartis AG may be deemed to share beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Novartis Pharma AG is the record holder of the securities reported herein. As the parent of Novartis Pharma AG, Novartis AG may be deemed to share beneficial ownership of these securities.
PRECISION BIOSCIENCES INC
Report date June 15, 2022 · Filed June 27, 2022
Jointly reported with NOVARTIS AG
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,407,440 |
Reported balance
Holding disclosure · report date 2022-06-15 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 12,407,440 F1: Novartis Pharma AG is the record holder of the securities reported herein. As the parent of Novartis Pharma AG, Novartis AG is the beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Novartis Pharma AG is the record holder of the securities reported herein. As the parent of Novartis Pharma AG, Novartis AG is the beneficial ownership of these securities.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Poseida Therapeutics, Inc.
Report date July 14, 2020 · Filed July 16, 2020
Jointly reported with NOVARTIS AG
Section 16 reporting ended · disclosed 2020-07-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,908,089 |
Reported balance
After 2020-07-14 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-07-14 · Conversion · Acquired 5,908,089 · Balance 5,908,089 F1: Each share of the Issuer's Series C Preferred Stock automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F2: These securities are owned directly by Novartis Pharma AG, a direct, wholly-owned subsidiary of Novartis AG. Novartis AG is an indirect beneficial owner of these securities. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-07-14 · Conversion · Disposed 7,367,387 · Balance 0 F1: Each share of the Issuer's Series C Preferred Stock automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F2: These securities are owned directly by Novartis Pharma AG, a direct, wholly-owned subsidiary of Novartis AG. Novartis AG is an indirect beneficial owner of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of the Issuer's Series C Preferred Stock automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date.
F2: These securities are owned directly by Novartis Pharma AG, a direct, wholly-owned subsidiary of Novartis AG. Novartis AG is an indirect beneficial owner of these securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2020 Filed Jul 16, 2020 16:53 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | ConversionSeries C Preferred Stock · Derivative | 7,367,387 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-084106 · a4.xml · derivative · entry 2 NOVARTIS PHARMA AG · CIK 0001030617 · 10% owner NOVARTIS AG · CIK 0001114448 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,908,089 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series C Preferred Stock automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series C Preferred Stock automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series C Preferred Stock automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series C Preferred Stock automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F2 · ownership.direct: These securities are owned directly by Novartis Pharma AG, a direct, wholly-owned subsidiary of Novartis AG. Novartis AG is an indirect beneficial owner of these securities. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 16:53 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | ConversionCommon Stock | 5,908,089 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-084106 · a4.xml · nonDerivative · entry 1 NOVARTIS PHARMA AG · CIK 0001030617 · 10% owner NOVARTIS AG · CIK 0001114448 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,908,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series C Preferred Stock automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F2 · ownership.direct: These securities are owned directly by Novartis Pharma AG, a direct, wholly-owned subsidiary of Novartis AG. Novartis AG is an indirect beneficial owner of these securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.